Equities Analysts Issue Forecasts for PTGX FY2026 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Investment analysts at HC Wainwright dropped their FY2026 EPS estimates for Protagonist Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $4.00 for the year, down from their previous estimate of $4.72. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $3.51 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q4 2026 earnings at ($0.90) EPS, FY2027 earnings at ($2.80) EPS, FY2028 earnings at ($2.45) EPS, FY2029 earnings at $0.12 EPS and FY2030 earnings at $1.46 EPS.

PTGX has been the subject of several other research reports. Citigroup boosted their price target on shares of Protagonist Therapeutics from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Protagonist Therapeutics in a report on Friday, May 15th. Wedbush boosted their target price on Protagonist Therapeutics from $118.00 to $173.00 and gave the stock an “outperform” rating in a research note on Monday. Wall Street Zen downgraded Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Wolfe Research started coverage on Protagonist Therapeutics in a research report on Thursday, May 21st. They issued an “outperform” rating and a $135.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.86.

Protagonist Therapeutics Stock Down 1.1%

Protagonist Therapeutics stock opened at $148.29 on Monday. Protagonist Therapeutics has a 52-week low of $53.49 and a 52-week high of $151.88. The firm has a market cap of $9.54 billion, a PE ratio of 143.97 and a beta of 1.78. The company’s 50 day moving average is $126.51 and its two-hundred day moving average is $106.30.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.02. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The firm had revenue of $213.47 million during the quarter, compared to analysts’ expectations of $212.03 million. The company’s revenue for the quarter was up 3746.8% compared to the same quarter last year.

Insider Activity at Protagonist Therapeutics

In other news, Director William D. Waddill sold 9,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total value of $1,061,460.00. Following the sale, the director directly owned 7,825 shares in the company, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 27,000 shares of company stock valued at $2,927,340. Corporate insiders own 5.19% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Several large investors have recently bought and sold shares of PTGX. Keating Financial Advisory Services Inc. acquired a new stake in Protagonist Therapeutics in the second quarter valued at $30,000. Allworth Financial LP acquired a new position in shares of Protagonist Therapeutics during the 2nd quarter worth about $31,000. E Fund Management Co. Ltd. acquired a new position in shares of Protagonist Therapeutics during the 2nd quarter worth about $477,000. Eagle Health Investments LP purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at about $30,439,000. Finally, Great Lakes Advisors LLC purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at about $6,975,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.